Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152
- PMID: 19188929
- DOI: 10.1038/tpj.2008.20
Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152
Abstract
AZD1152 is a highly selective Aurora B kinase inhibitor currently undergoing Phase I and II clinical evaluation in patients with acute myelogenous leukemia and advanced solid malignancies. We have established two AZD1152-resistant cell lines from SW620 colon and MiaPaCa pancreatic carcinoma lines, which are >100-fold resistant to the active metabolite of AZD1152, AZD1152 HQPA and interestingly, cross-resistant to the pan-Aurora kinase inhibitor, VX-680/MK0457. Using whole-genome microarray analysis and comparative genomic hybridization, we were able to identify MDR1 and BCRP as the causative genes that underlie AZD1152 HQPA-resistance in these models. Furthermore, the upregulation of either of these genes is sufficient to render in vivo tumor growth insensitive to AZD1152. Finally, the upregulation of MDR1 or BCRP is predictive of tumor cell sensitivity to this agent, both in vitro and in vivo. The data provide a genetic basis for resistance to Aurora kinase inhibitors, which could be utilized to predict clinical response to therapy.
Similar articles
-
Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.Mol Neurobiol. 2016 Apr;53(3):1808-1823. doi: 10.1007/s12035-015-9139-9. Epub 2015 Mar 11. Mol Neurobiol. 2016. PMID: 25752998
-
P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.BMC Cancer. 2011 Jun 16;11:254. doi: 10.1186/1471-2407-11-254. BMC Cancer. 2011. PMID: 21679421 Free PMC article.
-
Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.Mol Cancer. 2010 Feb 22;9:42. doi: 10.1186/1476-4598-9-42. Mol Cancer. 2010. PMID: 20175926 Free PMC article.
-
Dawn of Aurora kinase inhibitors as anticancer drugs.Expert Opin Investig Drugs. 2004 Sep;13(9):1199-201. doi: 10.1517/13543784.13.9.1199. Expert Opin Investig Drugs. 2004. PMID: 15330750 Review.
-
Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress.Semin Oncol. 2015 Dec;42(6):832-48. doi: 10.1053/j.seminoncol.2015.09.022. Epub 2015 Sep 24. Semin Oncol. 2015. PMID: 26615129 Review.
Cited by
-
Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.Molecules. 2021 Apr 1;26(7):1981. doi: 10.3390/molecules26071981. Molecules. 2021. PMID: 33915740 Free PMC article. Review.
-
hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations.Br J Cancer. 2010 Aug 10;103(4):567-74. doi: 10.1038/sj.bjc.6605724. Epub 2010 Jul 13. Br J Cancer. 2010. PMID: 20628378 Free PMC article.
-
Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.Mol Neurobiol. 2016 Apr;53(3):1808-1823. doi: 10.1007/s12035-015-9139-9. Epub 2015 Mar 11. Mol Neurobiol. 2016. PMID: 25752998
-
Design of new disubstituted imidazo[1,2-b]pyridazine derivatives as selective Haspin inhibitors. Synthesis, binding mode and anticancer biological evaluation.J Enzyme Inhib Med Chem. 2020 Dec;35(1):1840-1853. doi: 10.1080/14756366.2020.1825408. J Enzyme Inhib Med Chem. 2020. PMID: 33040634 Free PMC article.
-
The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducers.Cancer Drug Resist. 2023 Jul 27;6(6):468-480. doi: 10.20517/cdr.2023.29. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37840856 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous